Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions
Prostate Cancer
Interventions
DRUG

64Cu-DOTA-AE105

AE105 is a uPAR-specific peptide that is bound to the chelator DOTA, which in turn holds the diagnostic radionuclide copper-64 (64Cu), which can be detected upon decay by PET imaging.

Trial Locations (4)

7100

RECRUITING

Vejle Hospital, Vejle

20502

RECRUITING

Skåne University Hospital, Skåne

41345

RECRUITING

Sahlgrenska University Hospital, Gothenburg

Unknown

RECRUITING

Aalborg University Hospital, Aalborg

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

ABX CRO

OTHER

lead

Curasight

INDUSTRY